From: M2e-based universal influenza vaccines: a historical overview and new approaches to development
Major feature | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | Reference |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
The most conservative part of M2e | S | L | L | T | E | V | E | T | P | [18, 51] | ||||||||||||||
TCN-031 and TCN-032 antibodies recognition site | S | L | L | T | E | [37] | ||||||||||||||||||
O19 antibody recognition site | S | L | L | T | E | V | E | T | [32] | |||||||||||||||
L18 antibody recognition site | L | T | E | V | E | T | P | I | R | N | ||||||||||||||
S1 antibody recognition site | V | E | T | P | I | R | N | |||||||||||||||||
Influenza A and B virus neutralizing activity in vitro | S | L | L | T | E | V | E | T | P | I | R | [77] | ||||||||||||
Presence of B-cell epitope and 14C2 antibody recognition site | E | V | E | T | P | I | R | N | [78] | |||||||||||||||
High affinity of binding with HLA-A2; presence of T-cell epitope | L | L | T | E | V | E | T | P | I | [36] | ||||||||||||||
Potential epitope | E | T | P | I | R | [94] | ||||||||||||||||||
Presence of CTL-cell epitopes | S | L | L | T | E | V | E | T | P | I | R | N | E | W | G | |||||||||
Some critical residues for T-helpers | C | R | C | N | D | S | S | D | ||||||||||||||||
Recognition of HLA-B44-restricted CD8+ CTL line 124 | V | E | T | P | I | R | N | E | W | [52] | ||||||||||||||
MHC class II H-2d-restricted epitope | E | T | P | I | R | N | E | W | G | S | R | [26] | ||||||||||||
L66 antibody recognition site | S | L | L | T | E | V | E | T | P | I | R | N | E | W | G | [128] | ||||||||
N547 antibody recognition site | L | L | T | E | V | E | T | P | I | R | N | E | W | G | ||||||||||
Z3G1 antibody recognition site | L | L | T | E | V | E | T | P | I | R | ||||||||||||||
C40G1 antibody recognition site | T | P | I | R | N | E | ||||||||||||||||||
14C2 antibody recognition site | E | V | E | T | P | I | R | N | E | W |